0001193125-26-116030
SEC filingNuCana plc, a clinical-stage biopharmaceutical company, reported a net loss of $29.4 million for FY 2025 ended December 31, 2025, widening from $19.0 million in FY 2024, driven by higher finance expenses of $12.6 million from warrant revaluations and increased share-based payments of $10.0 million. Research and development expenses decreased to $12.7 million from $18.0 million YoY, reflecting reduced clinical trial costs, particularly for NuTide:323, partially offset by NuTide:701 expansion. Administrative expenses rose to $8.1 million from $5.0 million, mainly due to $2.5 million in higher share-based payments. No revenue was generated, consistent with pre-commercial status. Balance sheet strengthened with cash and equivalents at $24.3 million (up from $6.7 million), total assets $29.8 million, and equity $24.3 million. Net cash used in operations improved to $7.5 million from $19.1 million, supported by $4.0 million tax receipts. Financing activities provided $25.0 million, including $20.2 million from share issuances and $4.4 million from warrants. Outlook focuses on NuTide:701 Phase 2 data in 2026 and FDA guidance for NUC-7738 in melanoma, with cash runway into 2029. Strategic prioritization enhances liquidity amid ongoing losses.
NuCana plc reported FY2025 operating loss of $20.1M, driven by R&D $12.7M and admin $8.1M expenses. Net loss widened to $29.4M from $19.0M YoY, primarily due to $12.6M finance expense from warrant revaluations and $10.0M share-based payments. No revenue generated as clinical-stage biotech. Cash position strengthened to $24.3M from $6.7M, supporting runway into 2029. Equity $24.3M, total assets $29.8M. Net cash from financing $25.0M offset $7.5M ops outflow.
No revenue disclosed; pre-commercial focus on ProTides pipeline. Expenses segmented: R&D down 29% YoY to $12.7M (NuTide:701 $8.7M, NuTide:3373 $3.4M). Admin up 62% to $8.1M from share-based comp.
N/A; loss-making entity. Operating loss $20.1M vs prior. Finance costs $12.6M impacted pre-tax loss $30.5M. Tax credit $1.2M.
Ops cash use $7.5M (improved from $19.1M). Investing $0.2M inflow. Financing $25.0M (shares $20.2M, warrants $4.4M). Cash end $24.3M. Non-current assets $3.0M, current $26.9M. Liabilities $5.5M, equity $24.3M. Lease liabilities $0.7M.
NuTide:701 Phase 2 expansion data 2026; FDA guidance on NUC-7738 melanoma pathway. Evaluate NuTide:3373 combos/indications. Cash sufficient to 2029; potential funding needs for expansion.